Translumina launches SPARX global trial for drug-coated coronary balloons
October 13, 2026 | 15:25
Medical device company Translumina initiated the multinational SPARX randomized controlled trial to evaluate drug-coated balloon treatment strategies against conventional drug-eluting stents in coronary disease.
Mobile Version